Drugs / ChAdOx1.tHIVconsv1

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT06484335 Mar 2025 → Aug 2027 expected HIV infectious disease Henry M. Jackson Foundation for the Advancement of Military Medicine Recruiting No outcome recorded
Phase 1 NCT05604209 Oct 2022 → Sep 2024 HIV infectious disease University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 1 NCT04553016 Aug 2021 → Nov 2022 HIV infectious disease University of Oxford Unknown No outcome recorded
Phase 1 NCT04586673 Jul 2021 → Aug 2022 HIV infectious disease University of Oxford Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT06071767 Apr 2024 → Apr 2028 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07054931 Comparator Sep 2025 → Oct 2027 expected HIV infectious disease University of Oxford Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as ChAdOx1.tHIVconsv1 “The vaccine was administered as ChAdOx1.tHIVconsv1 (C1) followed by MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) in regimen C1-M3M4.” PMID 40388952 May 2025
5

NCT06484335

NCT05604209

NCT04586673

NCT06071767

NCT07054931

Modality Vaccine “Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised,...” PMID 40388952 May 2025
Route Intramuscular “At Week 0, volunteers receive 5.0 x 10\^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM).” NCT04553016